- Home
- DBD vs EVO Comparison
DBD vs EVO Comparison
Compare DBD & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- EVO
- Stock Information
- Founded
- DBD 1859
- EVO 1993
- Country
- DBD United States
- EVO Germany
- Employees
- DBD N/A
- EVO N/A
- Industry
- DBD EDP Services
- EVO Biotechnology: Pharmaceutical Preparations
- Sector
- DBD Technology
- EVO Health Care
- Exchange
- DBD Nasdaq
- EVO Nasdaq
- Market Cap
- DBD N/A
- EVO 1.5B
- IPO Year
- DBD N/A
- EVO 2021
- Fundamental
- Price
- DBD $46.37
- EVO $3.91
- Analyst Decision
- DBD Strong Buy
- EVO Buy
- Analyst Count
- DBD 2
- EVO 2
- Target Price
- DBD $65.00
- EVO $5.90
- AVG Volume (30 Days)
- DBD 149.8K
- EVO 148.6K
- Earning Date
- DBD 05-07-2025
- EVO 05-06-2025
- Dividend Yield
- DBD N/A
- EVO N/A
- EPS Growth
- DBD N/A
- EVO N/A
- EPS
- DBD N/A
- EVO N/A
- Revenue
- DBD $3,696,800,000.00
- EVO $851,944,444.00
- Revenue This Year
- DBD $1.70
- EVO $11.29
- Revenue Next Year
- DBD $1.89
- EVO $13.20
- P/E Ratio
- DBD N/A
- EVO N/A
- Revenue Growth
- DBD N/A
- EVO 1.50
- 52 Week Low
- DBD $34.38
- EVO $2.84
- 52 Week High
- DBD $51.81
- EVO $5.68
- Technical
- Relative Strength Index (RSI)
- DBD 61.13
- EVO 51.13
- Support Level
- DBD $43.61
- EVO $4.06
- Resistance Level
- DBD $46.64
- EVO $4.38
- Average True Range (ATR)
- DBD 1.43
- EVO 0.13
- MACD
- DBD 0.31
- EVO 0.00
- Stochastic Oscillator
- DBD 95.53
- EVO 48.35
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.